This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Hormone replacement therapy (HRT) safety profile

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

safety profile of HRT

Use of HRT for ≤5 years is safe and effective in a majority of symptomatic women.

The Women’s Health Initiative Study and the Nurses’ Health Study has estimated benefits and risks of oral HRT in postmenopausal women aged 50-59 years, or <10 years after menopause and according to these studies

  • majority of HRT related adverse effects increases with age
  • risks will differ with age and current health status (1)

The main risks which should be considered when on HRT are:

  • thromboembolic disease (venous thromboembolism and pulmonary embolism)
    • the risk is increased with oral HRT (in both combined and oestrogen only pills)
    • the type, dose and delivery system may also affect the risk
  • a recent systematic review found out that the risk of venous thromboembolism is incrased in oral HRT(but not transdermal)
  • in another large prospective observational study, the incidence of venous thromboembolism in low risk populations was not increased with low dose (≤1.5 mg oral, or ≤50 μg transdermal) oestradiol
    • hence a transdermal preparation and a reduced oestrogen dose is favored in women with increased risk of thromboembolic disease (1)
  • stroke
    • HRT increases the risk of stroke
    • HRT or tibolone should be avoided in women at high risk of stroke
  • cardiovascular disease
    • although the relationship between HRT and cardiovascular disease is questionable, the timing and duration of HRT, as well as pre-existing cardiovascular disease seems to have an effect on the outcome `
  • breast cancer
    • the risk of breast cancer diagnosis or breast cancer mortality is greater with combined HRT than with oestrogen alone
    • the risk with tibolone is not established (but large observational studies have shown an increased risk)
  • endometrial cancer
    • the risk is not increased with combined continuous HRT (when adequate duration and dose of progestogen are used) but risk may be increased with sequential HRT
    • risk of endometrial hyperplasia or cancer is not present in Tibolone users
  • gallbladder disease
    • HRT increases the risk of cholecystitis but can be reduced by using transdermal rather than oral HRT (1)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.